INT114956

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2002
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 9
Disease Relevance 1.56
Pain Relevance 0.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (CREBBP) small molecule metabolic process (CREBBP) protein complex assembly (CREBBP)
DNA binding (CREBBP) cytoplasm (CREBBP) signal transducer activity (CREBBP)
CREBBP (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 18 98.80 Very High Very High Very High
cINOD 72 89.16 High High
antagonist 41 69.24 Quite High
diclofenac 6 36.40 Quite Low
aspirin 35 5.00 Very Low Very Low Very Low
Kinase C 30 5.00 Very Low Very Low Very Low
Inflammation 15 5.00 Very Low Very Low Very Low
Arthritis 10 5.00 Very Low Very Low Very Low
rheumatoid arthritis 6 5.00 Very Low Very Low Very Low
cOX1 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 93 92.16 High High
INFLAMMATION 18 88.60 High High
Cancer 407 86.56 High High
Solid Tumor 5 82.96 Quite High
Repression 11 80.20 Quite High
Colon Cancer 52 71.60 Quite High
Adenoma 10 55.44 Quite High
Carcinoma 11 53.24 Quite High
Reprotox - General 1 1 49.52 Quite Low
Malignant Neoplastic Disease 10 32.60 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found that co-expression of PPAR delta, retinoid X receptor (RXR) alpha, and coactivators such as CBP and SRC-1 enhanced basal and agonist-dependent activation of PPAR responsive element (PPRE)-driven transcription by PPAR delta, rendering a PPRE-driven reporter assay reliable and sensitive.
Gene_expression (co-expression) of CBP associated with agonist
1) Confidence 0.31 Published 2003 Journal J. Pharmacol. Sci. Section Abstract Doc Link 14646253 Disease Relevance 0.24 Pain Relevance 0.55
We then assayed similarly expression levels for nuclear coactivators AIB1 [16], CBP [17], p300 [18], p/CIP [19], RAC3 [20], RIP140 [21], SRC1 [22], TIF1 [23], TIF2 [24] and TRIP1 [25].
Gene_expression (expression) of CBP
2) Confidence 0.11 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC113761 Disease Relevance 0 Pain Relevance 0
In mammalian cells, CBP/P300 can also act as a co-activator of ?
Gene_expression (/) of CBP
3) Confidence 0.09 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.42 Pain Relevance 0
-catenin synergizes with CBP to stimulate the transcriptional activation of ?
Gene_expression (synergizes) of CBP
4) Confidence 0.09 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.14 Pain Relevance 0.06
CBP/p300 potentiates ?
Gene_expression (/) of CBP
5) Confidence 0.09 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.12 Pain Relevance 0.07
Through inhibiting HDAC, CBP/P300 will no longer be able to function as a co-activator, and possibly even repress the ?
Gene_expression (/) of CBP
6) Confidence 0.09 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.51 Pain Relevance 0
CBP/p300 potentiates ?
Gene_expression (potentiates) of CBP
7) Confidence 0.09 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.12 Pain Relevance 0.07
For example, overexpression of CBP has been shown to prevent the inhibition of hPPAR?
Gene_expression (overexpression) of CBP
8) Confidence 0.04 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2716050 Disease Relevance 0 Pain Relevance 0
Both p300 and CBP can mediate acetylation of Rch1 and importin-?
Gene_expression (Both) of CBP
9) Confidence 0.04 Published 2002 Journal Genome Biol Section Body Doc Link PMC139359 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox